Today: 7 February 2026
Subscribe
Browse Category

Pharmaceuticals News 14 January 2026 - 15 January 2026

Pfizer stock edges higher as vaccine-policy jitters and obesity race frame the next catalyst

Pfizer stock edges higher as vaccine-policy jitters and obesity race frame the next catalyst

New York, Jan 15, 2026, 13:24 EST — Regular session Pfizer shares edged up roughly 0.3% to $25.67 on Thursday, finding footing after a volatile start to the year. Investors mulled over renewed discussions on U.S. vaccine policy alongside Pfizer’s growth strategy. The stock fluctuated between $25.26 and $25.67, with about 22.3 million shares changing hands. Why it matters now: vaccine makers face fresh political and demand challenges in the U.S. Sanofi CEO Paul Hudson warned of near-term “softness” in vaccine uptake, blaming “misinformation.” Pfizer CEO Albert Bourla expressed being “seriously frustrated,” labeling the trend as “political and antivax,” Reuters
15 January 2026
·····
Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

New York, Jan 15, 2026, 11:16 EST — Regular session. Pfizer Inc. shares fell 0.6% to $25.42 in late-morning trading on Thursday, extending a choppy start to the year for the drugmaker’s stock. The stock has struggled to find a clear driver since Pfizer warned in December that 2026 would likely start “bumpy,” with lower COVID-related sales, price cuts tied to a U.S. government deal and key patent expirations looming. Loss of exclusivity is shorthand for patents ending, which can open the door to cheaper rivals. (Reuters) The political noise around vaccines is back in focus. Sanofi Chief Executive Paul
15 January 2026
·········
AbbVie stock slides 2% as obesity push takes center stage at JPM conference

AbbVie stock slides 2% as obesity push takes center stage at JPM conference

New York, January 15, 2026, 12:11 (EST) — Regular session AbbVie shares dropped 2.1% to $217.13 Thursday following the company’s expanded plans for obesity treatments announced at the J.P. Morgan Healthcare Conference. This matters since AbbVie is hunting for its next major growth driver, as its aging blockbuster Humira grapples with increased competition from biosimilars. Investors have shown they’re eager to back solid obesity treatments—and just as ready to slam unclear prospects. Obesity drugs are turning into a fresh battleground for big pharma. Novo Nordisk and Eli Lilly currently lead the pack, but future victors may hinge on side effects,
15 January 2026
···
Johnson & Johnson stock slips as Tecvayli trial data lands ahead of earnings week

Johnson & Johnson stock slips as Tecvayli trial data lands ahead of earnings week

New York, Jan 15, 2026, 11:01 ET — Regular session Johnson & Johnson shares dipped Thursday following fresh late-stage data release for its Tecvayli cancer drug, with investors also bracing for next week’s earnings report. This update is crucial as Johnson & Johnson aims to expand the footprint of its newer drugs while shielding established products from pricing cuts and competition. Tecvayli plays a key role in the company’s blood cancer strategy, where even minor tweaks in labeling and timing can significantly impact sales momentum. Investors are now wondering if the latest data boosts Johnson & Johnson’s argument to push
15 January 2026
·····
GSK stock rises as pipeline talk hits JPM conference, with Feb. 4 earnings in focus

GSK stock rises as pipeline talk hits JPM conference, with Feb. 4 earnings in focus

New York, January 15, 2026, 02:30 EST — The market has closed. GSK plc’s shares traded in the U.S. climbed 1.8% on Wednesday, closing at $50.79. The stock remains in the spotlight heading into Thursday’s session. U.S. markets were closed overnight, leaving investors to watch for follow-through in premarket trading and in London after a week packed with conference headlines and positioning. The scene is set: investors are eager for clues on how major drugmakers intend to protect sales amid growing competition and aging products. For GSK, the coming weeks will focus on whether management can highlight new launches and
15 January 2026
······
Merck stock rises as $70 billion growth target sharpens focus ahead of Feb. 3 earnings

Merck stock rises as $70 billion growth target sharpens focus ahead of Feb. 3 earnings

New York, Jan 14, 2026, 20:15 EST — Market closed Merck & Co (Merck & Company, Inc., MRK) shares closed Wednesday up 2.54% at $111.01, rebounding from a short dip and holding close to recent peaks ahead of Thursday’s trading. This move is crucial as Merck works to reshape the conversation about what will follow Keytruda, its top-selling drug, once competition heats up later this decade. Investors have viewed the looming “patent cliff” as both a science challenge and a hit to the company’s valuation. Investors have been digging into management’s long-term projections at this week’s J.P. Morgan Healthcare Conference,
15 January 2026
·····
AbbVie stock in focus after hours as it eyes obesity market — what to watch next

AbbVie stock in focus after hours as it eyes obesity market — what to watch next

New York, Jan 14, 2026, 19:30 EST — After-hours AbbVie Inc’s shares climbed roughly 0.5% to $221.89 in after-hours trading Wednesday, following executives’ announcement to expand the company’s footprint in obesity treatments. During the regular session, the stock fluctuated between $217.84 and $223.27. The timing is crucial. AbbVie continues to push for growth beyond its legacy blockbusters as biosimilar competition intensifies — these cheaper copies of complex biologic drugs usually drive prices down. Investors are still ready to pay a premium for weight-loss drugs, even those early in development and costly. AbbVie is entering the fray belatedly, and Wall Street
15 January 2026
···
Pfizer stock rises as CEO bets on “Viagra-like” obesity demand; what investors watch next

Pfizer stock rises as CEO bets on “Viagra-like” obesity demand; what investors watch next

New York, Jan 14, 2026, 19:09 EST — After-hours Shares of Pfizer (PFE.N) climbed Wednesday as investors focused on the company’s move into obesity treatments, now the key battleground in the pharmaceutical sector. The stock closed regular hours roughly 1.7% higher, settling at $25.58. After-hours trading remained subdued. The obesity story is crucial for Pfizer as it seeks to regain steady growth following the drop-off in COVID-era sales and faces looming patent expirations on major drugs that could invite cheaper competitors. Management has warned investors that the coming years may bring some volatility. Obesity stands out as one of the
15 January 2026
···
Eli Lilly stock dips after hours as FDA seeks label change for Zepbound, traders eye obesity pill push

Eli Lilly stock dips after hours as FDA seeks label change for Zepbound, traders eye obesity pill push

NEW YORK, Jan 14, 2026, 6:33 PM EST — After-hours Eli Lilly shares slipped in after-hours trading Wednesday, as investors digested a U.S. regulatory update on weight-loss drug labels alongside new marketing chatter about the company’s upcoming obesity treatment. The FDA’s move to remove suicide warnings from GLP-1 weight-loss drugs comes at a tricky time for the sector. Demand is surging, competition is ramping up, and any change in safety signals could sway both prescribing habits and payer decisions. For Lilly, the timing coincides with efforts to expand its obesity franchise beyond injections. Traders are eyeing whether an oral pill
15 January 2026
····
Johnson & Johnson stock rises after Tecvayli trial win as JNJ eyes earnings

Johnson & Johnson stock rises after Tecvayli trial win as JNJ eyes earnings

New York, Jan 14, 2026, 18:15 EST — After-hours Johnson & Johnson shares climbed 2.3% to $218.55 in after-hours trading Wednesday following upbeat topline data from a late-stage multiple myeloma study for Tecvayli. Investors are zeroing in on Johnson & Johnson’s drug pipeline for the next growth phase as the company gears up for its quarterly report next week. Oncology continues to drive momentum, with myeloma standing out as a competitive yet profitable segment. The company reported that the Phase 3 MajesTEC-9 trial evaluated Tecvayli (teclistamab) alone versus standard treatments in patients previously treated with one to three therapy lines,
15 January 2026
·····
Pfizer (PFE) stock rises as CEO calls obesity push a “Viagra”-scale bet, with earnings next in focus

Pfizer (PFE) stock rises as CEO calls obesity push a “Viagra”-scale bet, with earnings next in focus

NEW YORK, Jan 14, 2026, 15:10 EST — Regular session Pfizer Inc shares climbed about 2% to $25.65 on Wednesday following CEO Albert Bourla’s remarks on the company’s push into the rapidly expanding cash-pay obesity drug market. “We are all in on obesity,” Bourla told reporters at the J.P. Morgan Healthcare Conference. Pfizer plans to launch 10 Phase 3 trials for its Metsera obesity compounds by the end of 2026, aiming to fuel future growth. The company still doesn’t expect revenue growth to return until 2029, as it navigates patent expirations and a slowdown in COVID-era sales. (Reuters) The shift
14 January 2026
····
Viridian Therapeutics stock jumps to a 52-week high as VRDN traders zero in on June FDA deadline

Viridian Therapeutics stock jumps to a 52-week high as VRDN traders zero in on June FDA deadline

New York, January 14, 2026, 14:14 EST — Regular session Viridian Therapeutics shares climbed 6.4% to $34.03 in early afternoon trading on Wednesday, after hitting an intraday high of $34.25, a new 52-week peak. The gain bucked a softer market. The Invesco QQQ Trust, a proxy for the Nasdaq 100, was down about 1.5%, while the SPDR S&P 500 ETF slid roughly 0.8%. Viridian, a Waltham, Massachusetts-based biotech, was valued at about $3.1 billion, according to Markets Insider data. (markets.businessinsider.com) The stock’s run has put more weight on a near-term regulatory clock. Viridian said in late December the U.S. Food
14 January 2026
·····
1 … 13 14 15 16 17 … 56

Stock Market Today

Lloyds share price steadies after buyback update and BoE rate jitters — what to watch next week

Lloyds share price steadies after buyback update and BoE rate jitters — what to watch next week

7 February 2026
Lloyds shares closed up 0.9% at 106.75 pence Friday after the bank announced fresh buybacks totaling 17 million shares over two days, all to be cancelled. The stock rebounded from a 5.6% drop Thursday as traders adjusted UK rate-cut bets. About 121 million Lloyds shares changed hands. Investors await the bank’s annual report on February 18 and the next Bank of England decision March 19.
Vodafone shares steady up after Q3 wobble — Germany, buyback and next results now set the tone

Vodafone shares steady up after Q3 wobble — Germany, buyback and next results now set the tone

7 February 2026
Vodafone shares rose 1.47% to 110.60p Friday, recovering part of Thursday’s 4.68% drop after a Q3 update. Group revenue climbed 6.5% to €10.5 billion, but Germany’s 0.7% service revenue growth missed some forecasts. Vodafone launched a new €500 million buyback tranche, bringing total buybacks since May to €3.5 billion. Investors remain focused on Germany’s pace and cash flow execution.
NatWest Group stock: buyback filing and Rightmove mortgage deal set up a busy week

NatWest Group stock: buyback filing and Rightmove mortgage deal set up a busy week

7 February 2026
NatWest shares closed up 1.45% at 659.4 pence Friday, buoyed by a buyback of 797,428 shares and a new digital mortgage deal with Rightmove. The Bank of England held rates at 3.75% but signaled possible cuts, with markets pricing in two reductions for 2026. NatWest plans to expand its Accelerator community to 50,000 members by 2026. Annual results are due Feb. 13.
Unilever share price holds at 5,250p as results week looms — what investors watch next

Unilever share price holds at 5,250p as results week looms — what investors watch next

7 February 2026
Unilever shares closed flat at 5,250p in London Friday, underperforming the FTSE 100’s 0.6% gain. The company issued 4.2 million new shares for employee plans, bringing total shares to over 2.18 billion. Investors await Q4 and full-year results on Feb. 12, with analyst consensus pointing to 3.9% Q4 sales growth. Unilever’s U.S. ADR rose 0.8% to $72.12.
Go toTop